From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study

Last Updated: Monday, September 25, 2023

A recent study evaluating patients 67 years or older with DLBCL found that pre-existing depression, anxiety, or both disorders (within 24 months before diagnosis) contribute to a worse prognosis. Patients with depression alone had the worst overall survival compared with no mental health disorder (HR 1.37, 95% CI 1.28–1.47), followed by those with depression and anxiety (HR 1.23, 95% CI 1.08–1.41), and then anxiety alone (HR 1.17, 95% CI 1.06–1.29). 

The Lancet Haematology
Advertisement
News & Literature Highlights

Journal of Clinical Oncology

Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma

OncLive

ctDNA testing joins NCCN Guidelines for MRD assessment in DLBCL

The Lancet

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

2024 American Society of Hematology Annual Meeting Abstract

Waveline-007: Dose escalation and confirmation, and efficacy expansion trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Open-label phase 2 study results of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States

2024 American Society of Hematology Annual Meeting Abstract

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

The Oncologist

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 

Advertisement
Advertisement